Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis

Overview

Journal J Bone Metab

Date 2021 Dec 14

PMID 34905678

Citations 8

Authors

Chaiho Jeong

Jinyoung Kim

Yejee Lim

Jeonghoon Ha

Moo Il Kang

Ki-Hyun Baek

Affiliations

Soon will be listed here.

Abstract

Background: Romosozumab has shown significant improvement in bone mineral density (BMD) in previously reported trials. However, BMD reflects only bone strength and does not offer insight into the bone microarchitecture. The trabecular bone score (TBS) is a non-invasive tool used to assess bone microarchitecture. Several previous studies have evaluated the efficacy of anti-osteoporotic agents using the TBS. However, data regarding the potency of romosozumab based on the TBS is lacking. This retrospective observational cohort study demonstrated the impact of romosozumab use on the TBS.

Methods: The primary outcome was the percentage change in the TBS from baseline to post-treatment. Postmenopausal osteoporosis patients were followed up for 6 and 12 months after romosozumab (210 mg monthly, N =10) and denosumab (60 mg every 6 months, N=21) or ibandronate (150 mg monthly, N=24) treatments, respectively. Patients who had previously used osteoporosis medications were included, if any the washout period was sufficient.

Results: The percentage change in TBS from baseline to post-treatment was 2.53±2.98% (6 months, N=10; P=0.04), 0.59%±3.26% (12 months, N=21; P=0.48), and -0.45±3.66% (12 months, N=24; P=0.51) in the romosozumab, denosumab, and ibandronate groups, respectively. Romosozumab demonstrated a noticeable increase in TBS, although it did not reach the least significant change (5.8%) in TBS.

Conclusions: Romosozumab improved the TBS in postmenopausal women with osteoporosis. TBS may be potentially useful for monitoring romosozumab treatment.

Citing Articles

Incident Vertebral Fractures During Romosozumab Treatment in a Patient With a Pathogenic Variant.

van Velsen E, Wijnen M, Muradin G, Zillikens M JCEM Case Rep. 2024; 3(1):luae238.

PMID: 39726666 PMC: 11669863. DOI: 10.1210/jcemcr/luae238.

Romosozumab improves microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis.

McClung M, Betah D, Leder B, Kendler D, Oates M, Timoshanko J J Bone Miner Res. 2024; 40(2):193-200.

PMID: 39656908 PMC: 11789382. DOI: 10.1093/jbmr/zjae194.

Monthly treatment with romosozumab for 1 year increases bone mineral at the hip, but not the knee, in women with chronic spinal cord injury.

Crack L, Simonian N, Schnitzer T, Edwards W JBMR Plus. 2024; 8(7):ziae077.

PMID: 38911320 PMC: 11193877. DOI: 10.1093/jbmrpl/ziae077.

Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis.

Hong N, Shin S, Lee S, Rhee Y Osteoporos Int. 2023; 34(12):2059-2067.

PMID: 37596432 DOI: 10.1007/s00198-023-06889-2.

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis.

Hu M, Zhang Y, Guo J, Guo C, Yang X, Ma X Front Endocrinol (Lausanne). 2023; 14:1188969.

PMID: 37529613 PMC: 10390296. DOI: 10.3389/fendo.2023.1188969.

References

Cosman F, Crittenden D, Adachi J, Binkley N, Czerwinski E, Ferrari S . Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016; 375(16):1532-1543. DOI: 10.1056/NEJMoa1607948. View

Rabier B, Heraud A, Grand-Lenoir C, Winzenrieth R, Hans D . A multicentre, retrospective case-control study assessing the role of trabecular bone score (TBS) in menopausal Caucasian women with low areal bone mineral density (BMDa): Analysing the odds of vertebral fracture. Bone. 2009; 46(1):176-81. DOI: 10.1016/j.bone.2009.06.032. View

Ramalho J, Marques I, Hans D, Dempster D, Zhou H, Patel P . The trabecular bone score: Relationships with trabecular and cortical microarchitecture measured by HR-pQCT and histomorphometry in patients with chronic kidney disease. Bone. 2018; 116:215-220. DOI: 10.1016/j.bone.2018.08.006. View

Arlot M, Meunier P, Boivin G, Haddock L, Tamayo J, Correa-Rotter R . Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res. 2005; 20(7):1244-53. DOI: 10.1359/JBMR.050309. View

Chavassieux P, Chapurlat R, Portero-Muzy N, Roux J, Garcia P, Brown J . Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment. J Bone Miner Res. 2019; 34(9):1597-1608. PMC: 7027577. DOI: 10.1002/jbmr.3735. View

McClung M, Lippuner K, Brandi M, Zanchetta J, Bone H, Chapurlat R . Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis. Osteoporos Int. 2017; 28(10):2967-2973. DOI: 10.1007/s00198-017-4140-y. View

Krohn K, Schwartz E, Chung Y, Lewiecki E . Dual-energy X-ray Absorptiometry Monitoring with Trabecular Bone Score: 2019 ISCD Official Position. J Clin Densitom. 2019; 22(4):501-505. DOI: 10.1016/j.jocd.2019.07.006. View

Senn C, Gunther B, Popp A, Perrelet R, Hans D, Lippuner K . Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int. 2014; 25(7):1945-51. DOI: 10.1007/s00198-014-2703-8. View

Saag K, Petersen J, Brandi M, Karaplis A, Lorentzon M, Thomas T . Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017; 377(15):1417-1427. DOI: 10.1056/NEJMoa1708322. View

10.

Silva B, Broy S, Boutroy S, Schousboe J, Shepherd J, Leslie W . Fracture Risk Prediction by Non-BMD DXA Measures: the 2015 ISCD Official Positions Part 2: Trabecular Bone Score. J Clin Densitom. 2015; 18(3):309-30. DOI: 10.1016/j.jocd.2015.06.008. View

11.

Bilezikian J, Hattersley G, Fitzpatrick L, Harris A, Shevroja E, Banks K . Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial. Osteoporos Int. 2017; 29(2):323-328. PMC: 5818587. DOI: 10.1007/s00198-017-4304-9. View

12.

Pothuaud L, Carceller P, Hans D . Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture. Bone. 2008; 42(4):775-87. DOI: 10.1016/j.bone.2007.11.018. View

13.

Touvier J, Winzenrieth R, Johansson H, Roux J, Chaintreuil J, Toumi H . Fracture discrimination by combined bone mineral density (BMD) and microarchitectural texture analysis. Calcif Tissue Int. 2015; 96(4):274-83. DOI: 10.1007/s00223-015-9952-1. View

14.

Boutroy S, Hans D, Sornay-Rendu E, Vilayphiou N, Winzenrieth R, Chapurlat R . Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. Osteoporos Int. 2012; 24(1):77-85. DOI: 10.1007/s00198-012-2188-2. View

15.

Popp A, Guler S, Lamy O, Senn C, Buffat H, Perrelet R . Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study. J Bone Miner Res. 2012; 28(3):449-54. DOI: 10.1002/jbmr.1775. View

16.

Majumdar S . A review of magnetic resonance (MR) imaging of trabecular bone micro-architecture: contribution to the prediction of biomechanical properties and fracture prevalence. Technol Health Care. 1999; 6(5-6):321-7. View

17.

Leib E, Winzenrieth R, Lamy O, Hans D . Comparing bone microarchitecture by trabecular bone score (TBS) in Caucasian American women with and without osteoporotic fractures. Calcif Tissue Int. 2014; 95(3):201-8. DOI: 10.1007/s00223-014-9882-3. View

18.

McClung M, Grauer A, Boonen S, Bolognese M, Brown J, Diez-Perez A . Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014; 370(5):412-20. DOI: 10.1056/NEJMoa1305224. View

19.

Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J . Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280(20):19883-7. DOI: 10.1074/jbc.M413274200. View

20.

Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg M . Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Densitom. 2011; 14(3):302-12. DOI: 10.1016/j.jocd.2011.05.005. View